信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2025

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the first quarter of 2025, the Company achieved total product revenue exceeding RMB2.4 billion, maintaining a robust growth of over 40% year-on-year. During this quarter, the Company successfully launched four new products, including Dovbleron® (taletrectinib), Limertinib, and Jaypirca® (pirtobrutinib) in the oncology field, as well as SYCUME® (teprotumumab N01 injection) in the general biomedicine field. During the quarter: 1) Innovent, as an established leading brand in oncology treatment, continued to see rapid growth in major oncology products, such as TYVYT® (sintilimab injection), while revenue contribution from new oncology products continued gaining momentum; and 2) products in the general biomedicine field began to emerge as new growth drivers, with SINTBILO® (tafolecimab injection) being newly included in the National Reimbursement Drug List, and the successful launch of SYCUME® (teprotumumab N01 injection) for thyroid eye disease.

The Company is committed to its core strategies of sustainable growth and global innovation, with a solid pipeline built in oncology and general biomedicines (which includes cardiovascular and metabolism, autoimmune, and ophthalmology). To date, the Company has 15 approved products, three new drug applications under regulatory review, four assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. The year 2025 is a significant year for the Company as it enters a new era of growth and global innovation, moving steadily towards its vision of becoming a premier global biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
May 1, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors.